Novartis prostate cancer drug trial meets primary endpoint
December 05, 2022 at 01:44 AM EST
The data will be submitted for regulatory approval next year to the U.S. Food and Drug Administration , Novartis said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|
© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.